|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Charakteristika predkladaného výstupu tvorivej činnosti /  Characteristics of the submitted research/ artistic/other output** | | | | | |
|  | | | | | |  | |
|  | |  | |  | |  | |
| *Tlačivo VTC slúži na predkladanie výstupov tvorivej činnosti podľa metodiky hodnotenia tvorivých činností (časť V. Metodiky na vyhodnocovanie štandardov) / The form is used to submit the research/artistic/other outputs according to the evaluation methodology of research/artistic/other activities (part V. The Methodology for Standards Evaluation).* | | | | | |  | |
|  | | | | | |  | |
|  | |  | |  | |  | |
|  | | [ID konania/ID of the procedure: 1](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | |  | |  | |
|  | | [Kód VTC/Code of the research/artistic/other output (RAOO):](file:///E:\\Šablony%20akreditácia\\4_VTC.xlsx" \l "'poznamky_explanatory notes'!A1)[1](file:///E:\\Šablony%20akreditácia\\4_VTC.xlsx" \l "'poznamky_explanatory notes'!A1) | |  | |  | |
|  | |  | |  | |  | |
| [OCA1. Priezvisko hodnotenej osoby / Surname awarded to the assessed person 2](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | Mrázová | |  | |
| [OCA2. Meno hodnotenej osoby / Name awarded to the assessed person 2](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | Mariana | |  | |
| [OCA3. Tituly hodnotenej osoby / Degrees awarded to the assessed person 2](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | prof. MUDr. Mgr. PhD, MHA. | |  | |
| [OCA4. Hyperlink na záznam osoby v Registri zamestnancov vysokých škôl / Hyperlink to the entry of the person in the Register of university staff 3](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | https://www.portalvs.sk/regzam/detail/12356 | |  | |
| [OCA5. Oblasť posudzovania / Area of assessment 4](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | Verejné zdravotníctvo I., II. a III.stupeň/ Public Health I . II. and III. Degree | |  | |
| [OCA6. Kategória výstupu tvorivej činnosti / Category of the research/ artistic/other output  *Výber zo 6 možností (pozri Vysvetlivky k položke OCA6) / Choice from 6 options (see Explanations for OCA6).*](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#Expl.OCA6!A1) | | | | A+, V3 Vedecký výstup / scientific output  IF 7,8 - 2022 | |  | |
| OCA7. Rok vydania výstupu tvorivej činnosti / Year of publication of the research/artistic/other output | | | | 2023 | |  | |
| [OCA8. ID záznamu v CREPČ alebo CREUČ *(ak je)* / ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA) 5](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | ID= 1087958 | |  | |
| [OCA9. Hyperlink na záznam v CREPČ alebo CREUČ / Hyperlink to the record in CRPA or CRAA 6](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | <https://app.crepc.sk/?fn=detailBiblioForm&sid=8A2420159ECD7877E155E20A8EC7> | |  | |
| Charakteristika výstupu, ktorý nie je registrovaný v CREPČ alebo CREUČ / Characteristics of the output that is not registered in CRPA or CRAA | | [OCA10. Hyperlink na záznam v inom verejne prístupnom registri, katalógu výstupov tvorivých činností / Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs 7](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | <https://pubmed.ncbi.nlm.nih.gov/37480426/> | |  | |
|  | | OCA11. Charakteristika výstupu vo formáte bibliografického záznamu CREPČ alebo CREUČ, ak výstup nie je vo verejne prístupnom registri alebo katalógu výstupov / Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs | | Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Caliskan, G., Violán, C., Torán-Monserrat, P., Vimercati, L., Tafuri, S., Boffetta, P., Violante, F. S., Sala, E., Sansone, E., Gobba, F., Casolari, L., Wieser, A., Janke, C., Tardon, A., Rodriguez-Suarez, M. M., Liviero, F., … Orchestra WP5 Working Group (2023). Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project. *Journal of epidemiology and global health*, *13*(3), 577–588. https://doi.org/10.1007/s44197-023-00139-8  Copy  Začiatok formulára  Download .nbib  Spodná časť formulára  For | |  | |
|  | | [OCA12. Typ výstupu (ak nie je výstup registrovaný v CREPČ alebo CREUČ) / Type of the output (if the output is not registered in CRPA or CRAA) *Výber zo 67 možností (pozri Vysvetlivky k položke OCA12) / Choice from 67 options (see Explanations for OCA12).*](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#Expl.OCA12!A1) | | vedecký výstup / scientific output | |  | |
|  | | OCA13. Hyperlink na stránku, na ktorej je výstup sprístupnený (úplný text, iná dokumentácia a podobne) / Hyperlink to the webpage where the output is available (full text, other documentation, etc.) | | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468456/ | |  | |
|  | | OCA14. Charakteristika autorského vkladu / Characteristics of the author's contribution | | Člen pracovnej skupiny ORCHESTRA WP5/ Orchestra WP5 Working Group 3,125% | |  | |
|  | | [OCA15. Anotácia výstupu s kontextovými informáciami týkajúcimi sa opisu tvorivého procesu a obsahu tvorivej činnosti a pod. / Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc. 8*Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in SlovakRozsah do 200 slov v anglickom jazyku / Range up to 200 words in English*](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | Multicentrická longitudinálna kohortová štúdia v rámci projektu ORCHESTRA, do ktorej bolo zapojených 63 516 zdravotníckych pracovníkov (HW) zo 14 európskych prostredí. Štúdia skúmala kumulatívny výskyt SARS-CoV-2 BI po posilňovacej dávke a jej koreláciu s vekom, pohlavím, povolaním, predchádzajúcou infekciou a časom od tretej dávky.  / Multicentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose. | |  | |
| [OCA16. Anotácia výstupu v anglickom jazyku / Annotation of the output in English  9*Rozsah do 200 slov / Range up to 200 words*](file:///E:\Šablony%20akreditácia\4_VTC.xlsx#'poznamky_explanatory notes'!A1) | | | | A multicentre retrospective cohort study of HW from 14 European centres involved in the ORCHESTRA project was performed [[12](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468456/#CR12)]. Data were collected from various healthcare settings (University Hospital, Primary healthcare centres, and nursing homes), in Germany (Munich), Italy (Bari, Bologna, Brescia, Modena, Padua, Perugia, Torino, Trieste, and Verona), Romania, Slovakia, and Spain (Northern Barcelona and Oviedo). This study was reported according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines [[13](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468456/#CR13)]. The follow-up started 14 days after the booster dose, administered from September 2021 to the 17th of May 2022, and ended on the 31st of May 2022 or at the time of BI. The median follow-up was 176 days (p25–p75 = 165–195 days). | |  | |
| OCA17. Zoznam najviac 5 najvýznamnejších ohlasov na výstup / List of maximum 5 most significant citations corresponding to the output  *Rozsah do 200 slov / Range up to 200 words* | | | | [Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project.](https://pubmed.ncbi.nlm.nih.gov/38326526/)  Spiteri G, D'Agostini M, Abedini M, Ditano G, Collatuzzo G, Boffetta P, Vimercati L, Sansone E, De Palma G, Modenese A, Gobba F, Liviero F, Moretto A, dell'Omo M, Fiordi T, Larese Filon F, Mauro M, Violán C, Mates D, Oravec Bérešová J, Monaco MGL, Carta A, Verlato G, Porru S.Infection. 2024 Feb 7. doi: 10.1007/s15010-024-02189-x. Online ahead of print.PMID: 38326526  [Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers.](https://pubmed.ncbi.nlm.nih.gov/38276662/)  Matula Z, Bekő G, Király V, Gönczi M, Zóka A, Baráth A, Uher F, Vályi-Nagy I.Vaccines (Basel). 2023 Dec 19;12(1):3. doi: 10.3390/vaccines12010003.PMID: 38276662  [The impact of SARS-CoV-2 on healthcare workers of a large University Hospital in the Veneto Region: risk of infection and clinical presentation in relation to different pandemic phases and some relevant determinants.](https://pubmed.ncbi.nlm.nih.gov/38098828/)  Liviero F, Volpin A, Furlan P, Battistella M, Broggio A, Fabris L, Favretto F, Mason P, Cocchio S, Cozzolino C, Baldo V, Moretto A, Scapellato ML.Front Public Health. 2023 Nov 30;11:1250911. doi: 10.3389/fpubh.2023.1250911. eCollection 2023.PMID: 38098828  [Learning from the Experience of the COVID-19 Pandemic: A New Paradigm for Occupational Biohazard Assessment and Management.](https://pubmed.ncbi.nlm.nih.gov/38060205/)  Durando P, Rahmani A, Montecucco A, Dini G.Med Lav. 2023 Dec 7;114(6):e2023056. doi: 10.23749/mdl.v114i6.15452.PMID: 38060205  [Risk of SARS-CoV-2 Reinfection 3 Years after the Start of the Pandemic: A Population-Level Observational Study.](https://pubmed.ncbi.nlm.nih.gov/38004251/)  Acuti Martellucci C, Flacco ME, Soldato G, Di Martino G, Carota R, Rosso A, De Benedictis M, Di Marco G, Di Luzio R, Lisbona F, Caponetti A, Manzoli L.Life (Basel). 2023 Oct 24;13(11):2111. doi: 10.3390/life13112111.PMID: 38004251  [Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project.](https://pubmed.ncbi.nlm.nih.gov/37480426/)  Porru S, Monaco MGL, Spiteri G, Carta A, Caliskan G, Violán C, Torán-Monserrat P, Vimercati L, Tafuri S, Boffetta P, Violante FS, Sala E, Sansone E, Gobba F, Casolari L, Wieser A, Janke C, Tardon A, Rodriguez-Suarez MM, Liviero F, Scapellato ML, dell'Omo M, Murgia N, Mates D, Calota VC, Strhársky J, Mrázová M, Pira E, Godono A, Magnano GC, Negro C, Verlato G; Orchestra WP5 Working Group.J Epidemiol Glob Health. 2023 Sep;13(3):577-588. doi: 10.1007/s44197-023-00139-8. Epub 2023 Jul 22.PMID: 37480426 | |  | |
| OCA18. Charakteristika dopadu výstupu na spoločensko-hospodársku prax / Characteristics of the output's impact on socio-economic practice  *Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English* | | | | Prelomové infekcie SARS-CoV-2 (BI) po podaní posilňovacej dávky vakcíny sú relevantným problémom verejného zdravia. Riziko BI po posilňovacej dávke výrazne znižuje predchádzajúca infekcia, heterológne očkovanie a vyšší vek. Imunosupresia je relevantná pre zvýšený výskyt BI. Čas, ktorý uplynul od posilňovacej dávky, ovplyvňuje závažnosť BI, čo potvrdzuje užitočnosť posilňovacej dávky pre verejné zdravie. Ďalší výskum by sa mal zamerať na trend BI po 4. dávke a jeho vzťah s časovými premennými v rámci epidémií.  /SARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue. The risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics. | |  | |
| OCA19. Charakteristika dopadu výstupu a súvisiacich aktivít na vzdelávací proces / Characteristics of the output and related activities' impact on the educational process *Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English* | | | | Očkovacia kampaň proti SARS-CoV-2 sa začala koncom roka 2020 a preukázala vysokú účinnosť v prevencii infekcie a závažnosti ochorenia u jedincov, ktorí absolvovali kompletný očkovací cyklus. V kontexte motivácie populácie je nevyhnutná edukácia širokej verejnosti a v prvom rade odbornej. Výstupy boli odovzdávané vzdelávaním participantov aj študentov  /The vaccination campaign against SARS-CoV-2 started at the end of 2020 and showed high effectiveness in preventing infection and severity of disease in subjects who had received a complete vaccination course  In the context of the motivation of the population, education of the general public and, first of all, professional education is essential. The outputs were handed over to the participants and students | |  | |